Moleculin Biotech Inc. (MBRX)
NASDAQ: MBRX
· Real-Time Price · USD
0.67
0.02 (3.43%)
At close: Aug 15, 2025, 2:37 PM
3.43% (1D)
| Bid | 0.66 |
| Market Cap | 20.17M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -23.23M |
| EPS (ttm) | -3.74 |
| PE Ratio (ttm) | -0.18 |
| Forward PE | -0.5 |
| Analyst | Buy |
| Ask | 0.67 |
| Volume | 537,018 |
| Avg. Volume (20D) | 5,415,232 |
| Open | 0.66 |
| Previous Close | 0.65 |
| Day's Range | 0.63 - 0.67 |
| 52-Week Range | 0.25 - 3.65 |
| Beta | 1.40 |
About MBRX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol MBRX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for MBRX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 month ago
+14.54%
Moleculin Biotech shares are trading higher after ...
Unlock content with
Pro Subscription
1 month ago
+34.1%
Moleculin Biotech shares are trading higher after the company announced it has been granted European Patent Number EP3990041 titled "METHOD OF RECONSTITUTING LIPOSOMAL ANNAMYCIN (FOR THE TREATMENT OF CANCER).
